Giant cell arteritis is the most common form of vasculitis in adults over 50, an inflammatory disease in which the immune system attacks the walls of medium-to-large arteries, particularly the temporal arteries at the sides of the head and, in many cases, the aorta and its major branches. It affects roughly 10 out of every 100,000 people over 50 each year, with rates varying sharply by geography and ancestry.1PubMed Central. A meta-analysis of the epidemiology of giant cell arteritis across time and space Left untreated, it can cause permanent blindness within days, which is why it is treated as a medical emergency. But the disease extends well beyond the eyes, and the way it behaves, how it is diagnosed, and what treatment looks like have all shifted meaningfully in recent years.
Who Gets Giant Cell Arteritis
GCA almost exclusively strikes people over 50, and the risk climbs with every decade after that. Women are affected roughly two to three times more often than men. Geography matters too: Scandinavian countries report the highest rates, around 22 cases per 100,000 people over 50, while southern Europe sees far lower numbers, sometimes below 10 per 100,000.2PubMed Central. A meta-analysis of the epidemiology of giant cell arteritis across time and space A separate systematic review found that the highest incidence in individual studies ranged from about 15 to 44 per 100,000 in Scandinavia and the UK, while estimates in southern Europe clustered between 1 and 11 per 100,000.3PubMed. Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review The disease appears to be less common in non-Caucasian populations, though limited study of these groups makes firm conclusions difficult.
There is a genetic component. The strongest known link is with a set of immune-system genes in the HLA region, particularly a variant called HLA-DRB1*04. A large genetic study found that variants in this region carried one of the highest risks for GCA susceptibility, with an odds ratio of about 1.7.4The American Journal of Human Genetics. A Large-Scale Immunochip Analysis Identifies HLA and Non-HLA Loci Associated with Giant Cell Arteritis Earlier work had shown that about 60% of biopsy-confirmed GCA patients carried disease-linked HLA-DR4 variants, and that the relevant genetic sequence mapped to the part of the immune cell responsible for presenting foreign material to T cells.5JCI Insight. The HLA-DRB1 locus as a genetic component in giant cell arteritis Beyond HLA, other immune-related genes involving molecules like tumor necrosis factor and intercellular adhesion molecule 1 (ICAM-1) seem to play additional roles.6PubMed Central. Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica None of this means GCA is inherited the way a single-gene condition would be. It means certain immune-system configurations make people more vulnerable, and those configurations happen to be most common in populations of northern European descent.
What Happens Inside the Artery Wall
GCA is fundamentally a disease of mistaken immune activation. It starts when specialized immune cells called dendritic cells, which normally sit in the artery wall and monitor for threats, begin recruiting T cells into the vessel wall as though responding to an infection that isn’t there.7PubMed Central. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications Those T cells then activate macrophages, which are the immune system’s heavy-duty cleanup crew, and together they form clusters of inflammation called granulomas. Some macrophages fuse into the disease’s hallmark feature: multinucleated giant cells, the structures that give the condition its name.
Part of the reason this immune response spirals out of control is a failure of the body’s normal braking system. A checkpoint pathway called PD-1/PD-L1, which ordinarily tells immune cells to stand down when they are no longer needed, does not work properly in the affected artery walls. Without that brake, multiple types of T cells thrive in the tissue, shift toward aggressive energy-consuming behavior, and drive ongoing damage.8PubMed Central. Immunology of Giant Cell Arteritis The inflammatory mix includes two important branches of the immune response. One, driven by Th17 cells, tends to respond well to steroid treatment. The other, driven by Th1 cells that produce a signal molecule called interferon-gamma, persists even after steroids suppress the initial flare.9PubMed Central. Th17 and Th1 T-cell responses in giant cell arteritis This dual-pathway biology explains a frustrating clinical reality: steroids bring rapid symptom relief, but the disease often smolders and relapses when doses are lowered.
A signaling molecule called interleukin-6 (IL-6) plays a central role in amplifying inflammation. Patients with stronger systemic inflammatory responses have significantly higher IL-6 levels in their artery tissue.10Rheumatology. Tissue production of pro-inflammatory cytokines (IL-1β, TNFα and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis That finding underpins the success of a newer treatment that blocks the IL-6 receptor, discussed further below.
Symptoms and How They Overlap With Polymyalgia Rheumatica
The classic presentation of GCA is a new, persistent headache, usually centered at one or both temples. A meta-analysis found headache was the single most frequent symptom. Other common features include abnormalities of the temporal artery visible or felt on exam, general weakness or fatigue, and tenderness of the scalp.11PubMed. Headache as the most common manifestation of giant cell arteritis?: a systematic review with meta-analysis Jaw claudication, a cramping ache in the jaw muscles during chewing that eases when you stop, is less frequent but more specific to GCA. One study found jaw claudication in about 42% of biopsy-confirmed cases and showed it was among the strongest predictors of a positive diagnosis.12PubMed Central. Temporal headache and jaw claudication may be the key for the diagnosis of giant cell arteritis
An important wrinkle is the overlap with polymyalgia rheumatica (PMR), a condition that causes aching and stiffness in the shoulders, hips, and neck. The two diseases are closely related and frequently occur together.13PubMed. Polymyalgia rheumatica and giant-cell arteritis In biopsy-proven GCA, up to half of patients also have PMR symptoms, and PMR can sometimes be the first sign of the disease before the more recognizable headache and jaw symptoms appear.14PubMed. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions Anyone diagnosed with PMR who develops a new headache, visual changes, or jaw pain should be evaluated promptly for GCA.
Large Vessel Disease and Why Some Cases Are Hard to Spot
GCA does not always target the temporal arteries. A subtype known as large vessel GCA primarily affects the aorta and its major branches, often without producing the classic headache and tender temples.15The Lancet Rheumatology. Large vessel giant cell arteritis Patients with large vessel GCA tend to be younger at diagnosis by about four and a half years and take about three months longer to be diagnosed. Fewer of them have a positive temporal artery biopsy, and only about half meet the traditional classification criteria developed in 1990.16PubMed. Clinical phenotype and complications of large vessel giant cell arteritis: A systematic review and meta-analysis The most common sites of inflammation are the thoracic aorta and the subclavian arteries.
This variant matters because constitutional symptoms like fever, weight loss, and fatigue can be its primary or only complaints, which makes it easy to mistake for something else entirely. It is a recognized cause of “fever of unknown origin” in older adults. The diagnostic delay is not just academic: prolonged uncontrolled inflammation of the aorta raises the risk of serious vascular complications over time.
Vision Loss and Aortic Complications
The most feared acute complication of GCA is vision loss, which typically happens because inflamed arteries cut off blood flow to the optic nerve. The usual culprit is involvement of the short posterior ciliary arteries that supply the front of the optic nerve, causing a condition called anterior arteritic ischemic optic neuropathy.17PubMed. Vision loss in giant cell arteritis Vision loss from GCA tends to come on suddenly and is often irreversible, which is why any suspicion of the disease warrants immediate steroid treatment, even before the diagnosis is confirmed. In some cases, one eye is affected first, and without rapid treatment the other eye can follow within days.
The longer-term vascular risk involves the aorta itself. A population-based study found that patients with GCA were over 17 times more likely to develop a thoracic aortic aneurysm than people of the same age and sex in the general population. Among 96 tracked patients, 11 developed thoracic aortic aneurysms, most of them emerging a median of nearly six years after the original GCA diagnosis. Six of those 11 died of sudden aortic dissection.18PubMed. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study A later prospective study that re-screened GCA patients found that about a third had developed aortic structural damage, primarily in the thoracic segment, with aortic diameters increasing over time.19PubMed. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation) This is why many specialists recommend periodic imaging of the aorta for years after diagnosis, even in patients whose symptoms have resolved.
How GCA Is Diagnosed
Temporal artery biopsy has long been considered the gold standard. A small segment of the temporal artery is removed and examined under a microscope for characteristic inflammation and giant cells. The test is very specific, meaning a positive result almost certainly confirms the disease, but its sensitivity is imperfect. One review put the sensitivity at about 77% with a specificity approaching 100%, while another meta-analysis estimated a lower sensitivity of around 61%.20PubMed Central. Temporal artery biopsy for suspected giant cell arteritis: A mini review21PubMed Central. Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments The gap comes from so-called skip lesions, where inflammation is patchy rather than continuous, so the sampled segment may happen to miss an affected area.
Temporal artery ultrasound has emerged as a noninvasive alternative. When the artery wall is inflamed, ultrasound can detect a dark ring around the vessel known as a “halo sign.” When seen on both sides, the halo sign is highly specific for GCA.22PubMed Central. Halo Sign on Temporal Artery Ultrasound Aids in Prompt Diagnosis of Giant Cell Arteritis In 2022, the American College of Rheumatology updated its classification criteria for GCA and gave the ultrasound halo sign the same diagnostic weight as a positive temporal artery biopsy.23PubMed. 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis Those updated criteria use a point-based system: age 50 or older is required, and then items such as biopsy or halo sign (+5 points), elevated inflammatory markers (+3), sudden vision loss (+3), and various symptoms and imaging findings (+2 each) are tallied. A score of 6 or more classifies a patient as having GCA.
For suspected large vessel GCA, especially when the biopsy is negative, PET/CT scanning can detect inflammation in the aorta and its branches. In patients with GCA and a negative biopsy, PET/CT showed a sensitivity of about 84% and specificity of about 85% for large vessel involvement.24PubMed Central. Usefulness of (18)F-FDG PET-CT for assessing large-vessel involvement in patients with suspected giant cell arteritis and negative temporal artery biopsy A head-to-head comparison found that cranial PET/CT matched or exceeded temporal artery ultrasound in sensitivity for cranial disease, at 83% versus 55%, without sacrificing specificity.25PubMed. Direct comparison of the diagnostic accuracy of PET/CT, cranial MRI, ultrasound and temporal artery biopsy in giant cell arteritis In practice, many centers now use ultrasound as a rapid first-line test and reserve biopsy or PET/CT for cases where the ultrasound is negative but clinical suspicion remains high.
Treatment With Glucocorticoids
High-dose glucocorticoids (steroids) remain the first-line treatment and should be started as soon as GCA is suspected, not delayed until biopsy results return. Current recommendations typically call for oral prednisolone at 40 to 60 mg per day. For patients with vision symptoms or recent vision loss, many clinicians begin with intravenous methylprednisolone at 500 to 1,000 mg daily for three days before transitioning to oral steroids.26Rheumatology. The use of intravenous methylprednisolone in giant cell arteritis: a population-based study The response is often dramatic: headache and jaw pain may ease within hours to a day or two, and inflammatory markers drop rapidly.
The problem is what comes next. Steroids need to be tapered slowly over many months, and flares are common during the taper. The cumulative steroid exposure is substantial. Real-world data from the US and UK found median starting doses of 20 to 50 mg per day and cumulative doses of around 4,000 to 4,800 mg in the first year after diagnosis.27PubMed Central. Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK That much steroid over that long a period carries real consequences: more than 80% of patients experience steroid-related side effects.28PubMed Central. Giant cell arteritis: Current treatment and management A dose-response pattern has been documented across a range of complications, with higher cumulative doses linked to increasing rates of new-onset type 2 diabetes, serious infections, cataracts, gastrointestinal bleeding, and weight gain.29PubMed Central. Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database Bone density loss and osteoporotic fractures are also well-recognized consequences of prolonged steroid use, and most GCA patients will need bone-protective therapy during treatment.
Tocilizumab and the Push to Reduce Steroid Burden
The arrival of tocilizumab, a drug that blocks the IL-6 receptor, was a turning point. A landmark trial published in the New England Journal of Medicine compared tocilizumab plus a short steroid taper to placebo plus longer steroid tapers. About 56% of patients on weekly tocilizumab achieved sustained remission at one year, compared with only 14 to 18% of those on steroids alone. Crucially, the tocilizumab groups accumulated far less total steroid exposure, roughly half the cumulative prednisone dose of the placebo groups.30New England Journal of Medicine. Trial of Tocilizumab in Giant-Cell Arteritis That matters enormously given the side-effect profile of prolonged steroids.
Tocilizumab is now widely used as a first-line steroid-sparing agent in GCA.31PubMed Central. Biologic Therapies for Giant Cell Arteritis It is typically given as a weekly subcutaneous injection or a monthly intravenous infusion. One practical consideration: because tocilizumab suppresses IL-6, it also suppresses the blood markers (CRP and ESR) that doctors rely on to monitor disease activity. That means a normal CRP in someone on tocilizumab does not necessarily mean the disease is quiet, making clinical assessment of symptoms even more important during treatment.
Monitoring for Relapse
GCA tends to follow a relapsing-remitting course, and tracking disease activity matters. The standard blood markers are erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), both of which rise sharply during active inflammation. A prospective study of GCA patients being tapered off steroids found that those who relapsed had significantly higher ESR and CRP at the visit closest to their flare compared to baseline, confirming these markers’ usefulness as warning signals in patients not on IL-6 blockade.32Rheumatology. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis—a prospective longitudinal study Phase 2 trial data have also supported using CRP and ESR elevations alongside recurrent clinical symptoms to define relapse in clinical trials.33Arthritis & Rheumatology. Utility of CRP and ESR in the Assessment of Giant Cell Arteritis Relapse in a Phase 2 Trial of Mavrilimumab
Many patients need treatment for two years or longer. Some achieve lasting remission; others flare repeatedly and require ongoing immunosuppression. There is currently no reliable way to predict at diagnosis who will have a single episode and who will have a chronic course, which is one of the field’s biggest unmet needs.
What Treatment Does to Quality of Life
GCA’s burden goes beyond the direct symptoms. Qualitative research with patients identified dozens of distinct ways the disease affects daily life, spanning physical symptoms, ability to carry out everyday activities, social participation, psychological well-being, and the patient’s sense of self and perception of their own health.34PubMed Central. Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure A disease-specific quality-of-life measure (the GCA-PRO) was developed from this work, reflecting how deeply the combination of disease symptoms and steroid side effects can reshape someone’s life over months and years.35PubMed Central. Validation of a patient-reported outcome measure for giant cell arteritis
Patients frequently describe the frustration of managing steroid-driven weight gain, mood changes, insomnia, and muscle weakness on top of the disease itself. For people with vision loss, the psychological impact can be profound and lasting. Acknowledging these experiences and addressing steroid side effects proactively, through bone-density screening, blood-sugar monitoring, and sleep support, is as much a part of GCA management as controlling the inflammation.
Emerging Therapies Beyond Tocilizumab
Tocilizumab was a major advance, but it does not work for everyone. Some patients cannot tolerate it, others flare despite being on it, and the Th1-driven component of the disease that persists despite steroid treatment also appears to persist in some patients on IL-6 blockade. Researchers are testing drugs that target other parts of the immune cascade. Mavrilimumab, which blocks a growth factor called GM-CSF that helps macrophages survive and multiply, has shown promise in phase 2 data. JAK inhibitors, a class of drugs already approved for rheumatoid arthritis, represent another avenue. A case report documented a patient with GCA refractory to both an IL-6 blocker and an IL-17 blocker who achieved clinical and imaging remission on upadacitinib, a selective JAK1 inhibitor.36PubMed Central. Giant Cell Arteritis Refractory to Interleukin-6 and Interleukin-17 Inhibition Treated With Upadacitinib A single case report is thin evidence, but it illustrates the direction the field is moving: toward treatments that target the specific immune pathways driving disease in a given patient, rather than relying on the blunt, broad suppression that steroids provide.
Other approaches under investigation include abatacept, which interferes with T cell activation, and secukinumab, which blocks IL-17. The hope is that within the next decade, clinicians will have enough targeted options to tailor treatment to the individual patient’s disease biology, significantly reducing the need for long-term high-dose steroids and the damage they cause.
How Medical Understanding of GCA Evolved
Descriptions of what appears to be GCA date back to at least the tenth century, but the modern understanding began in 1890 when the British surgeon Jonathan Hutchinson described an older man whose inflamed temporal arteries prevented him from wearing a hat.37PubMed. Horton’s disease: past and present That report was largely forgotten. In 1932, the American physician Bayard Horton obtained the first temporal artery biopsies, described the microscopic appearance of the disease, and was also the first to document jaw claudication. He initially misidentified the cause as a fungal infection before recognizing it as a distinct form of arteritis.38PubMed. Bayard Horton’s clinicopathological description of giant cell (temporal) arteritis The disease was still called “Horton’s disease” in some countries until relatively recently. Through the 1950s and 1960s, the many presentations and complications of GCA were gradually cataloged, and the connection to polymyalgia rheumatica was recognized.39PubMed. The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970 That slow recognition partly explains why the disease still catches people off guard: it took decades for physicians to realize just how many different ways GCA can present, and the large vessel subtype was not widely appreciated until advanced imaging made it visible.